Alpha Stem Cell Clinic

Section 1

COVID-19 Plasma Study
Current Clinical Trials
Meet the ASCC Staff

About

The Alpha Stem Cell Clinic (ASCC) provides a centralized infrastructure from which to work with UCI faculty and staff to enhance stem cell clinical research and activities at UCI. The UCLA-UCI Alpha Stem Cell Clinic:

  • Is part of the California Institute for Regenerative Medicine (CIRM) Alpha Stem Cell Clinic network
  • Promotes and facilitates scientific collaborations and interactions
  • Provides centralized clinical research infrastructure support
  • Accelerates the implementation of clinical research trials

CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges »

Clinical Trials

placeholder

Takeda Crohn’s Disease: The ADMIRE-CDII Study

The purpose of this study is to confirm how well Cx601 works compared to a placebo, and how safe and tolerable Cx601 is compared to placebo for the treatment of complex perianal fistula(s) in subjects with Crohn’s disease.

COVID-19 Convalescent Plasma Study

Individuals who have recovered from COVID-19 develop proteins called antibodies in the part of their blood called plasma. Because these antibodies can block COVID-19 infection, the U.S Food and Administration has authorized the transfusion of plasma isolated from COVID-19 convalescent donors to treat severely ill individuals and help them fight the disease.

placeholder

Location & Contact

UCI Alpha Stem Cell Clinic

Gross Hall: A CIRM Institute

University of California, Irvine
845 Health Sciences Road
1001 Gross Hall
Irvine, CA 92697-1705

Phone: (949) 824-3990
Email: stemcell@uci.edu